Faon

Faon is a clinical-stage biotechnology company based in South Korea that specializes in the development of next-generation immuno-oncology therapeutics. The company's primary focus is on engineering bispecific fusion proteins designed to simultaneously inhibit multiple immunosuppressive pathways within the tumor microenvironment. Its lead program, FAON-101, is a first-in-class bifunctional fusion protein that targets both the PD-L1 and TGF-beta pathways to restore anti-tumor immune responses. By leveraging its proprietary protein engineering platform, Faon aims to address the limitations of current checkpoint inhibitors and provide more effective treatment options for patients with hard-to-treat solid tumors.